Anixa Biosciences Inc. (NASDAQ:ANIX) Chief Executive Officer Amit Kumar has executed a significant equity purchase, acquiring 21,000 shares of the company's common stock. The transaction, documented in a recent filing with the Securities and Exchange Commission, took place on June 12, 2026. At an acquisition price of $2.50 per share, the total value of the purchase reached $52,500. This activity directly increases Kumar's direct ownership stake in Anixa Biosciences to 630,812 shares.
The executive purchase coincides with the stock trading near its 52-week low of $2.32, a notable decline from its 52-week high of $5.46. Despite the stock price trajectory, Anixa maintains a strong balance sheet characterized by a current ratio of 9.79. The company holds $13.7 million in cash and investments as of the end of the quarter ending April 30, 2026. For that same period, Anixa reported a net loss of $2.5 million, equating to $0.07 per share.
Market analysis from H.C. Wainwright has reiterated a Buy rating on Anixa, maintaining a price target of $7.00 following the fiscal second-quarter results. The firm's assessment comes amid several clinical and regulatory milestones. Anixa received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its ovarian cancer vaccine technology. This patent, licensed from the Cleveland Clinic, addresses methods to elicit an immune response against ovarian cancer. Additionally, the company secured a Mexican patent for its breast cancer vaccine, extending intellectual property protection through 2040.
Clinical progress remains a focal point. Anixa announced survival data from its Phase 1 trial of liraltagene autoleucel, a CAR-T therapy designed for recurrent ovarian cancer. The data indicates that several patients survived beyond expected median survival times. Furthermore, Anixa's ovarian cancer therapy was highlighted at the International Society for Cell & Gene Therapy 2026 Annual Meeting. The stock closed at $2.48 on June 15, with pre-market trading showing a gain to $2.53.